Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: Results of a phase II study

Journal of Clinical Oncology

Volumn 28, Issue 30, 2010, Pages 4635-4641

  Ludwig, Heinz ^a   Adam, Zdenek ^a   Hajek, Roman ^a   Greil, Richard ^a   Tóthová, Elena ^a   Keil, Felix ^a   Autzinger, Eva Maria ^a   Thaler, Josef ^a   Gisslinger, Heinz ^a   Lang, Alois ^a   Egyed, Miklós ^a   Womastek, Irene ^a   Zojer, Niklas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN LIGHT CHAIN; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFECTION; KIDNEY FUNCTION; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEAKNESS; DISEASE FREE SURVIVAL; EUROPE; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; EUROPE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; PYRAZINES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78049507882     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.1238     Document Type: Article

References (35)

1. Kyle RA, Gertz MA, Witzig TE, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21-33, 2003 (Pubitemid 36033957)
2. Bladé J, Fernández-Llama P, Bosch F, et al: Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158:1889-1893, 1998
3. Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma: Pathogenesis and prognostic implications. Arch Intern Med 150:1693-1695, 1990 (Pubitemid 20240982)
4. Torra R, Bladé J, Cases A, et al: Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91:854-859, 1995
5. Kleber M, Ihorst G, Deschler B, et al: Detection of renal impairment as one specific comorbidity factor in multiple myeloma: Multicenter study in 198 consecutive patients. Eur J Haematol 83:519-527, 2009
6. Dimopoulos MA, Kastritis E, Rosinol L, et al: Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485-1493, 2008
7. Ma CX, Lacy MQ, Rompala JF, et al: Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 104:40-42, 2004 (Pubitemid 38879834)
8. Herrera GA, Joseph L, Gu X, et al: Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128:875-879, 2004 (Pubitemid 39014119)
9. Ying WZ, Sanders PW: Mapping the binding domain of immunoglobulin light chains for Tamm- Horsfall protein. Am J Pathol 158:1859-1866, 2001
10. Jennette JC, Olson JL, Schwartz MM, et al: Heptinstall's Pathology of the Kidney. Philadelphia, PA, Lippincott Williams & Wilkins, 1998
11. Sengul S, Zwizinski C, Simon EE, et al: Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int 62:1977-1988, 2002
12. Schwartz R, Davidson T: Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park) 18:14-21, 2004 (suppl 11)
13. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al: Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: Identification of predictive factors. Clin Lymphoma Myeloma 9:302-306, 2009
14. Jagannath S, Barlogie B, Berenson JR, et al: Bortezomib in recurrent and/or refractory multiple myeloma: Initial clinical experience in patients with impaired renal function. Cancer 103:1195-1200, 2005 (Pubitemid 40328090)
15. Chanan-Khan AA, Kaufman JL, Mehta J, et al: Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multi-center retrospective study. Blood 109:2604-2606, 2007 (Pubitemid 46425908)
16. Ludwig H, Drach J, Graf H, et al: Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92:1411-1414, 2007 (Pubitemid 350144160)
17. Dimopoulos MA, Richardson PG, Schlag R, et al: VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study. J Clin Oncol 27:6086-6093, 2009
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Peto R, Peto J: Asymptotically efficient rank invariation test procedures (with discussion). J R Stat Soc A 135:185-206, 1972
20. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
21. Roussou M, Kastritis E, Migkou M, et al: Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49:890-895, 2008 (Pubitemid 351942741)
22. Li J, Zhou DB, Jiao L, et al: Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymphoma Myeloma 9:394-398, 2009
23. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1-S266, 2002 (suppl 1)
24. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
25. Wardle EN: Antagonism of nuclear factor kappa B. Nephron 90:239, 2002
26. Tosi P, Zamagni E, Cellini C, et al: Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 73:98-103, 2004 (Pubitemid 38980109)
27. Eriksson T, Höglund P, Turesson I, et al: Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 55:1701-1706, 2003 (Pubitemid 38054404)
28. Pineda-Roman M, Tricot G: High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol 153:182-194, 2007 (Pubitemid 44836021)
29. Kastritis E, Dimopoulos MA: The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 8:497-509, 2007 (Pubitemid 46416418)
30. Chen N, Lau H, Kong L, et al: Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466-1475, 2007 (Pubitemid 350115306)
31. Rajkumar SV, Jacobus S, Callander NS, et al: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29-37, 2010
32. Reece DE, Masih-Khan E, Chen C, et al: Use of lenalidomide (Revlimid) +/- corticosteroids in relapsed/refractory multiple myeloma patients with elevated baseline serum creatinine levels. Blood 108:3548, 2006 (abstr)
33. Ludwig H, Zojer N: Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nat Rev Clin Oncol 7:289-294, 2010
34. Brenner H, Gondos A, Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111:2521-2526, 2008
35. Lonial S, Richardson PG, San Miguel J, et al: Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 143:222-229, 2008